## CDNA: CareDx, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.2% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.75)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. CareDx, Inc. Reaches Preliminary Settlement in Shareholder Derivative Litigation**
- Source: TradingView — Track All Markets | 20251218T220935 | Neutral | Relevance: 100%
- CareDx, Inc. has received preliminary court approval for a settlement in a shareholder derivative lawsuit, focusing on corporate governance reforms. The settlement, which includes audit committee enhancements and compliance reviews, addresses claims of false statements and oversight failures. A final approval hearing is scheduled for June 30, 2026, in California, and no individual stockholder compensation is part of this agreement.

**2. CareDx Provides Notice of Proposed Derivative Settlement**
- Source: Yahoo Finance | 20251219T020935 | Neutral | Relevance: 100%
- CareDx, Inc. (Nasdaq: CDNA) has issued a notice regarding a proposed settlement of shareholder derivative actions, including Edelman et al. v. Bickerstaff et al. and Edward W. Burns IRA v. Goldberg, et al. The settlement involves the implementation of corporate governance reforms designed to benefit CareDx, rather than direct payments to individual stockholders. A final approval hearing for the settlement is scheduled for June 30, 2026, where the Court will consider the terms, attorney's fees, and any objections.

**3. Squarepoint Ops LLC Has $2.77 Million Stock Holdings in CareDx, Inc. $CDNA**
- Source: MarketBeat | 20251218T110935 | Somewhat-Bullish | Relevance: 100%
- Squarepoint Ops LLC reduced its stake in CareDx, Inc. ($CDNA) by 34.3% in Q2, bringing its total holdings to 141,683 shares valued at $2.77 million. Despite this, CareDx reported strong Q2 earnings, beating analyst expectations with $0.28 EPS and $100.06 million in revenue, coupled with a 19.65% net margin. Analysts generally rate the stock as "Hold" with an average price target of $26.67, although opinions vary.

**4. CareDx Wins Preliminary Court Approval for Derivative Settlement**
- Source: TipRanks | 20251218T220935 | Somewhat-Bullish | Relevance: 100%
- CareDx (CDNA) has secured preliminary court approval for a settlement in a shareholder derivative lawsuit concerning alleged misleading statements by its current and former directors and officers. The settlement, which aims to resolve federal and Delaware actions, is pending final approval at a hearing scheduled for June 30, 2026. Spark, TipRanks’ AI Analyst, rates CDNA as "Outperform" due to its strong financial performance and positive outlook.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $18 | $14 | +29% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 4 ($0.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 1 |

**Top Holders:**
- Blackrock Inc.: 9.3% (+2.3%)
- Vanguard Group Inc: 7.3% (-23.6%)
- BAMCO Inc.: 6.1% (+29.5%)
- State Street Corpora: 5.0% (+17.7%)
- Ophir Asset Manageme: 4.3% (+16.1%)

### Key Risks

1. High beta (2.54) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_20 falling (-7.4% 5d) with bearish MACD, trend may be turning.
3. Elevated short interest (13.1%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Forward P/E 22.3x attractive for 27% earnings growth. Quality metrics strong (ROE 24%, margin 20%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.39). Analyst sentiment positive (1 raises, avg +29%). Institutional flow bullish (9 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.0B |
| Beta | 2.54 |
| 52W Range | $10.96 - $25.95 |
| Short Interest | 13.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.12 |
| Forward P/E | 22.3 |
| Current P/E | 28.3 |
| YoY Growth | 26.9% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 10.7% to 3.2% (-7.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.8pp (needs >4.0% for momentum thesis). MRS_5 (-1.3%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.6% shows strong absolute momentum above own 20MA. Outperforming sector by 3.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLH (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.25% (CS: 79) | Neutral |
| RSI_14 | 60.1 | Neutral |
| MACD Histogram | -0.07 | Bearish |
| vs SMA20 | 1.036x | Above |
| vs SMA50 | 1.169x | Above |
| vs SMA200 | 1.191x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $19.45
- **Stop Loss:** $17.75 (8.7% risk)
- **Target:** $21.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 705
- **Position Value:** $13,712.25
- **Portfolio %:** 13.71%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-03-02 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.14 | $0.28 | +97.6% |
| 2025Q2 | $0.12 | $0.10 | -18.0% |
| 2025Q1 | $0.07 | $0.10 | +46.4% |
| 2024Q4 | $0.15 | $0.18 | +22.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*